Caris Life Sciences (CAI) Stock Price

Caris Life Sciences Price

NYSE·CLOSED
17.58
​
Market closed

Revenue has compounded at 13.8% per year over the past 20 years to 812.03 M USD. Earnings per share have grown at 29.0% per year over the last 15 years. Caris Life Sciences's net margin stands at -66.2%, down from 9.4% several years earlier. Caris Life Sciences currently offers a dividend yield of about 5.12%. The payout ratio is around 32% of earnings. Analysts set a median price target of 38.00 USD, implying 116.2% above the current price. Of 16 analysts, 12 rate the stock a buy — an overall Buy consensus.

Caris Life Sciences stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Caris Life Sciences business model & stock analysis

CAI International, Inc. generates revenue through leasing intermodal shipping containers and railcars to customers under long-term, short-term, and finance leases, with terms of one year or more specifying container quantities and locations. The company operates two reportable segments: container leasing and logistics, managing equipment for third-party investors while providing domestic and international logistics services. Its fleet includes containers and railcars that are leased, re-leased, or disposed of, with additional services covering repair, repositioning, and storage. The firm serves lessees requiring container solutions for transportation and logistics needs. The company's primary customers are businesses needing container leasing for intermodal shipping, including logistics providers and transportation companies. CAI International manages equipment for third-party investors, creating a secondary revenue stream through asset management. The logistics segment offers domestic and international services, targeting clients requiring comprehensive supply chain solutions. Revenue is derived from lease payments, equipment management fees, and logistics service contracts. Container leasing forms the core of the business, with long-term leases being a significant portion of revenue. The firm's operations involve purchasing, leasing, and managing equipment, including repositioning and storage services. The logistics segment complements the leasing business by providing additional value through integrated transportation solutions. Equipment disposal also contributes to revenue when containers are sold after their lease terms.

Frequently asked questions about Caris Life Sciences

Analysts currently set an average price target of 34.00 USD for the Caris Life Sciences stock (median: 38.00 USD), implying +93.4 % versus the latest price. The consensus is based on 16 analyst ratings.

16 analysts currently rate the Caris Life Sciences stock: 12 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Caris Life Sciences to generate revenue of 1.04 B USD and earnings per share of 0.11 USD.

Converted at the current exchange rate, the Caris Life Sciences share trades at 16.02 EUR (17.58 USD).

The Caris Life Sciences share (CAI) is listed on 1 stock exchanges, including: NYSE (CAI).

The expected revenue of Caris Life Sciences is 1.04 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Caris Life Sciences is 31.95 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Caris Life Sciences is currently 159.52. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Caris Life Sciences stock.

The price-to-sales ratio (P/S) of Caris Life Sciences is currently 4.88. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Caris Life Sciences stock.

The Eulerpool Quality Score for Caris Life Sciences is 5/10.

The ISIN of Caris Life Sciences is US1421521071. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Caris Life Sciences is A0MLRM. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Caris Life Sciences is CAI. The ticker symbol is used to trade Caris Life Sciences shares on the stock exchange.

Fair ValueTerminal
17.05 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Trading Companies & Distributors
Number of shares
Employees
Revenue per Employee
3.72 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website capps.com
Currency
USD
Initial public offering
Feb 7, 2007
ISIN
US1421521071
Cusip
12477X106
Sedol
B1VZ4J7
Market capitalization
4.96 B USDMid Cap
52-Week Range
PEG
-0.23
P/E ratio
P/Ee 2026
155.26
P/Ee 2027
62.78
P/Ee 2028
39.85
P/Ee 2029
27.61
P/Ee 2030
27.69
P/S
P/Se
4.88
EV/EBIT
100.67
P/B Ratio
8.59
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-56.25 %
Last updated Nov 22, 2026, 3:42 AM

Caris Life Sciences Ticker

NEW YORK · CAI